局部治疗联合系统治疗在不可切除肝癌中的研究进展  

Research progress of locoregional therapies combined with systemic therapies in unresectable hepatocellular carcinoma

作　　者：景聪敏 张玉宝[1] Jing Congmin;Zhang Yubao(Department of Hepatobiliary Surgery,Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院肝胆外科,哈尔滨150081

出　　处：《肝癌电子杂志》2024年第4期50-53,共4页Electronic Journal of Liver Tumor

基　　金：北京医学奖励基金北京医学奖励基金(YXJL-2022-0080-0168)。

摘　　要：肝癌在我国恶性肿瘤发病率中居第5位,肿瘤相关致死原因中居第2位。大多数肝癌患者待出现特征性症状时病变已属于中晚期并失去最佳手术治疗时机,因此姑息治疗在肝细胞癌的治疗中占核心地位。局部治疗是不可手术切除肝细胞癌(u HCC)患者的主要治疗方案之一,免疫治疗、靶向治疗等系统治疗近年来也取得了实质性进展,但单用介入手段或单药治疗的效果有限,而多种联合治疗方案在临床研究中积极探索并取得了肯定的疗效,为u HCC患者的治疗带来了希望。局部治疗联合系统治疗的新组合预计是中晚期肝癌潜在的治疗模式。现将局部治疗联合系统治疗的研究现状进行综述,旨在为u HCC患者提供更多治疗策略。Liver cancer ranks fifth in the incidence of malignant tumors and second in the causes of cancer-related death in China.Most of the patients have already developed to the middle and late stages when characteristic symptoms appear,have missed the best time for surgery,so palliative therapy plays a central role in the treatment of hepatocellular carcinoma.Locoregional treatment is one of the main therapeutic options for patients with unresectable hepatocellular carcinoma(uHCC),and immunotherapy and targeted systemic therapy have also made substantial progress in recent years,but the effect of interventional therapy alone or monotherapy is limited.Several combination therapy options have been actively explored in clinical studies,with encouraging efficacy and brought hope for the treatment of uHCC patients.Among them,the new combination of locoregional combined with systemic therapy is expected to be a potential therapeutic modality for intermediate and advanced hepatocellular carcinoma.This review provides an overview of the current status of research on locoregional combined with systemic therapy,aim to provide more treatment strategies for uHCC patients.

关 键 词：局部治疗 系统治疗 肝细胞癌 研究进展 

分 类 号：R73[医药卫生—肿瘤]